Open Access

Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review)

  • Authors:
    • Jin Shang
    • Lingyao Du
    • Ning Han
    • Duoduo Lv
    • Jiayi Wang
    • Hailing Yang
    • Lang Bai
    • Hong Tang
  • View Affiliations

  • Published online on: February 8, 2021     https://doi.org/10.3892/mmr.2021.11901
  • Article Number: 262
  • Copyright: © Shang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recently, severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 (SARS‑CoV‑2)‑causing CoV disease 2019 (COVID‑19) emerged in China and has become a global pandemic. SARS‑CoV‑2 is a novel CoV originating from β‑CoVs. Major distinctions in the gene sequences between SARS‑CoV and SARS‑CoV‑2 include the spike gene, open reading frame (ORF) 3b and ORF 8. SARS‑CoV‑2 infection is initiated when the virus interacts with angiotensin‑converting enzyme 2 (ACE2) receptors on host cells. Through this mechanism, the virus infects the alveolar, esophageal epithelial, ileum, colon and other cells on which ACE2 is highly expressed, causing damage to target organs. To date, host innate immunity may be the only identified direct factor associated with viral replication. However, increased ACE2 expression may upregulate the viral load indirectly by increasing the baseline level of infectious virus particles. The peak viral load of SARS‑CoV‑2 is estimated to occur ~10 days following fever onset, causing patients in the acute stage to be the primary infection source. However, patients in the recovery stage or with occult infections can also be contagious. The host immune response in patients with COVID‑19 remains to be elucidated. By studying other SARS and Middle East respiratory syndrome coronaviruses, it is hypothesized that patients with COVID‑19 may lack sufficient antiviral T‑cell responses, which consequently present with innate immune response disorders. This may to a certain degree explain why this type of CoV triggers severe inflammatory responses and immune damage and its associated complications.
View Figures
View References

Related Articles

Journal Cover

April-2021
Volume 23 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shang J, Du L, Han N, Lv D, Wang J, Yang H, Bai L and Tang H: Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review). Mol Med Rep 23: 262, 2021
APA
Shang, J., Du, L., Han, N., Lv, D., Wang, J., Yang, H. ... Tang, H. (2021). Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review). Molecular Medicine Reports, 23, 262. https://doi.org/10.3892/mmr.2021.11901
MLA
Shang, J., Du, L., Han, N., Lv, D., Wang, J., Yang, H., Bai, L., Tang, H."Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review)". Molecular Medicine Reports 23.4 (2021): 262.
Chicago
Shang, J., Du, L., Han, N., Lv, D., Wang, J., Yang, H., Bai, L., Tang, H."Severe acute respiratory syndrome coronavirus 2 for physicians: Molecular characteristics and host immunity (Review)". Molecular Medicine Reports 23, no. 4 (2021): 262. https://doi.org/10.3892/mmr.2021.11901